ABT monthly performance report
Monthly ABT research: returns, drawdown, relative strength, seasonality, and key stats.
ABT monthly report
—
Key takeaways
- Abbott Laboratories (ABT) closed August 2026 at $105.71, up 0.01% for the month and −19.11% over the trailing 12 months.
- Year-to-date, ABT is −15.63%, underperforming the S&P 500 which has returned +12.89% YTD.
- The stock is trading −2.44% versus its 200-day moving average ($108.35), a cautious technical signal.
- Over the past three years, ABT has underperformed the S&P 500 by −74.09%, with a relative strength index reading of 57.1.
- Win rate over the trailing 39 months stands at 51.3% — 20 positive months versus 19 negative months.
Abbott Laboratories ended August 2026 at $105.71, posting a monthly return of +0.01%. The S&P 500 returned +3.05% over the same window, leaving relative performance at −3.04%.
The current quarter stands at +14.51% (Q3 2026 (QTD)), while medium-term trend remains soft: price is −2.44% versus the 200-day moving average ($108.35).
Year-to-date, ABT is −15.63% against SPY +12.89%, a gap of −28.51%. The stock is currently −23.11% below its 52-week high, with maximum 3-year drawdown at −41.12%.
| Period | ABT | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +0.24% | −0.20% | +0.44% |
| 1 Week | −1.45% | +3.90% | −5.36% |
| 1 Month | +0.01% | +3.05% | −3.04% |
| 3 Months | +16.43% | +7.11% | +9.32% |
| 6 Months |